# One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™

> **NCT02962284** · PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 20 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** abiraterone acetate with Methylprednisolone

## Key facts

- **NCT ID:** NCT02962284
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-03
- **Final completion:** 2018-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962284, "One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02962284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*